Document Detail


Effect of protein kinase C and phospholipase A2 inhibitors on the impaired ability of human diabetic platelets to cause vasodilation.
MedLine Citation:
PMID:  10433497     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
1. The aim of this study was to examine the mechanism of impaired platelet-mediated endothelium-dependent vasodilation in diabetes. Exposure of human platelets to high glucose in vivo or in vitro impairs their ability to cause endothelium-dependent vasodilation. While previous data suggest that the mechanism for this involves increased activity of the cyclo-oxygenase pathway, the signal transduction pathway mediating this effect is unknown. 2. Platelets from diabetic patients as well as normal platelets and normal platelets exposed to high glucose concentrations were used to determine the role of the polyol pathway, diacylglycerol (DAG) production, protein kinase C (PKC) activity and phospholipase A2 (PLA2) activity on vasodilation in rabbit carotid arteries. 3. We found that two aldose-reductase inhibitors, tolrestat and sorbinil, caused only a modest improvement in the impairment of vasodilation by glucose exposed platelets. However, sorbitol and fructose could not be detected in the platelets, at either normal or hyperglycaemic conditions. We found that incubation in 17 mM glucose caused a significant increase in DAG levels in platelets. Furthermore, the DAG analog 1-oleoyl-2-acetyl-sn-glycerol (OAG) caused significant impairment of platelet-mediated vasodilation. The PKC inhibitors calphostin C and H7 as well as inhibitors of PLA2 activity normalized the ability of platelets from diabetic patients to cause vasodilation and prevented glucose-induced impairment of platelet-mediated vasodilation in vitro. 4. These results suggest that the impairment of platelet-mediated vasodilation caused by high glucose concentrations is mediated by increased DAG levels and stimulation of PKC and PLA2 activity.
Authors:
H J Oskarsson; T G Hofmeyer; L Coppey; M A Yorek
Related Documents :
7033097 - Increased platelet prostaglandin and thromboxane synthesis in diabetes mellitus.
20604957 - The combined effects of sidestream smoke extracts and glycated serum albumin on endothe...
21964487 - Platelet-rich plasma induces increased expression of g1 cell cycle regulators, type i c...
21043597 - Does reduced membrane lipid fluidity underlie the altered thrombin-induced expression o...
16384677 - Antithrombotic activity of methanolic extract of umbilicaria esculenta.
20523167 - Activation of pak1/2 during the shedding of platelet microvesicles.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  British journal of pharmacology     Volume:  127     ISSN:  0007-1188     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  1999 Jun 
Date Detail:
Created Date:  1999-08-26     Completed Date:  1999-08-26     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  903-8     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University of Iowa and Veterans Administration Medical Center, Iowa City, USA. HOSKARSSON@hprhs.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Animals
Blood Platelets / physiology*
Diabetes Mellitus / blood*
Diglycerides / biosynthesis
Female
Glucose / metabolism,  pharmacology
Humans
Male
Middle Aged
Naphthalenes / pharmacology
Phospholipases A / antagonists & inhibitors,  physiology*
Phospholipases A2
Protein Kinase C / antagonists & inhibitors,  physiology*
Rabbits
Sorbitol / metabolism
Terpenes / pharmacology
Vasodilation*
Grant Support
ID/Acronym/Agency:
DK-25295/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Diglycerides; 0/Naphthalenes; 0/Terpenes; 121263-19-2/calphostin C; 50-70-4/Sorbitol; 50-99-7/Glucose; 75088-80-1/manoalide; 82964-04-3/tolrestat; EC 2.7.11.13/Protein Kinase C; EC 3.1.1.-/Phospholipases A; EC 3.1.1.4/Phospholipases A2
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium.
Next Document:  Interactions between cholecystokinin and opioids in the isolated guinea-pig ileum.